Sorry, you need to enable JavaScript to visit this website.

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • October 11, 2022
  • Glomerular Disease

Guiding you through Glomerular Disease: an interactive approach to learning more on IgAN and FSGS

Explore the science
  • October 11, 2022
  • Glomerular Disease

IgAN Mechanism of Disease

Explore the science
  • September 05, 2022
  • Hyperkalemia

Global Heart Failure Academy

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: A steroid-sparing option

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Compassionate use of Avacopan in difficult-to-treat ANCA-associated vasculitis

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Exploring the unmet needs of people suffering with ANCA-associated vasculitis (AAV)

Explore the science
  • June 08, 2022
  • Hyperkalemia

Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Emerging opportunities and challenges in SHPT

Explore the science
  • February 18, 2022
  • Hyperkalemia

The latest KDIGO guidelines support the use of next-generation potassium binders for the management of chronic hyperkalemia

Explore the science